[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arterial-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arterial-thrombosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100488921","registry-on-augmented-antithrombotic-treatment-regimens-for-patients-with-arterial-thrombotic-aps-100488921",false,"NCT05646394","Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","Inclusion Criteria:\n\n1. Patients of at least 18 years of age with confirmed antiphospholipid syndrome according to Sydney criteria and with first or recurrent arterial thrombotic manifestation, including those with asymptomatic brain infarcts on diagnostic imaging.\n2. Treatment with either A) a vitamin K antagonist (VKA) with therapeutic range, international normalized ratio (INR) 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0 or C) VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen, if considered appropriate by the treating physician.\n3. Signed informed consent obtained (in jurisdictions where required).\n\nExclusion Criteria:\n\n1. Inability to follow the patient due to geographical or other reasons.\n2. Patients with documented poor compliance.\n3. Bleeding risk that in the opinion of the treating physician makes combination antithrombotic therapy unsafe.\n4. Pregnancy or planned pregnancy.\n5. Venous thrombotic event diagnosed after the last arterial event.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.",[24,25],"Antiphospholipid Syndrome","Arterial Thrombosis",[27,28,29,30,31,32],"anticoagulation","vitamin K antagonist","antiaggregant","stroke","myocardial infarction","hemorrhage","RECRUITING","2025-12-02",{"date":36,"type":37},"2025-12-09","ACTUAL",{"date":39,"type":37},"2022-07-01",{"date":41,"type":19},"2029-12-31",{"name":43,"class":44},"McMaster University","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100555992","immune-checkpoint-inhibitor-associated-cardiovascular-adverse-events-in-patients-with-cancer-100555992","NCT06519292","Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer","ITHACA","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma\n* Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)\n* Age ≥ 50 years\n\nExclusion Criteria:\n\n* ICI therapy in previous 12 months\n* Suspected or confirmed viral, fungal, or bacterial infectious disease\n* Use of immunosuppressive therapy prior to ICI start\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Known allergy to iodinated contrast agents\n* Atrial fibrillation","50 Years",{"count":55,"type":19},214,"Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system in the body. Recently, concerns have also risen about cardiovascular effects of ICI. Retrospective studies showed an 4-5 times increased risk of developing an arterial thromboembolic event.\n\nThe mechanisms driving the ICI-associated risks of arterial thromboembolic events such as myocardial infarction and stroke, are unclear. Since the risk of a thromboembolism appears to be increased already during the first months after initiation of ICI, immune-related hypercoagulability or (autoimmune) antiphospholipid antibodies may play a role, but data to support this are lacking. The longer-term risk of arterial thromboembolism may be predominantly driven by (accelerated) atherosclerosis, a chronic low-grade inflammatory disease of the larger arteries. Therefore, this study evaluates the effect of ICI on progression of coronary non-calcifid plaque volume by using computed tomography angiography (CCTA).",[58,25,59,60,61,62,63],"Cardiovascular Diseases","Myocardial Infarction","Stroke","Coronary Artery Disease","Atherosclerosis","Cancer",[65,66,67],"immune checkpoint inhibitors","cardiovascular disease","atherosclerosis","2025-05-20",{"date":70,"type":37},"2025-05-22",{"date":72,"type":37},"2023-01-25",{"date":74,"type":19},"2025-12-31",{"name":76,"class":44},"Hanneke W. M. van Laarhoven",1]